查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584122

癌症支持治疗药物市场，按药物类型、治疗领域、分布、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Cancer Supportive Care Drugs Market, By Drug Type, By Therapeutic Area, By Distribution, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 301 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年癌症支持治疗药物市场规模为2,141,032万美元，2024年至2032年复合年增长率为2.31%。

癌症支持治疗药物市场-市场动态

癌症发生率上升加速癌症支持治疗药物市场的成长

随着越来越多的患者寻求治疗方法来控制与治疗相关的副作用，癌症发病率的上升极大地推动了癌症支持治疗药物市场的成长。据世界卫生组织(WHO) 称，癌症目前是全球第二大死亡原因，2020 年将有近1000 万人死亡。癌症治疗的患者的生活品质。例如，美国临床肿瘤学会 (ASCO) 强调控制癌症患者中常见的噁心、疼痛和疲劳等症状的重要性。此外，国家癌症研究所等组织正在倡导研究新型支持性护理药物，进一步扩大了对有效治疗的需求。随着医疗保健提供者扩大对全面癌症护理的关注，支持疗法市场预计将蓬勃发展，反映出在这一充满挑战的健康环境中改善患者治疗结果的迫切需求。

癌症支持治疗药物市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 2.31% 左右的复合年增长率成长

根据药物类型细分，预计止吐药将在 2023 年显示最大的市场份额

根据治疗区域细分，化疗引起的噁心和呕吐是 2023 年的主要类型

从分布细分来看，医院药局是2023年的主导类型

按地区划分，北美是 2023 年的主要收入来源

癌症支持治疗药物市场-細項分析：

全球癌症支持治疗药物市场根据药物类型、治疗领域、分布、最终用户和地区进行细分。

根据药物类型，市场分为四类：红血球生成刺激剂、粒细胞集落刺激因子（G-CSF）、止吐剂和双磷酸盐。由于止吐剂在控制化疗引起的噁心和呕吐方面发挥重要作用，预计将占据最大的市场份额。红血球生成刺激剂紧跟在后，因为它们有助于对抗癌症患者的贫血。粒细胞集落刺激因子 (G-CSF) 也很重要，支持化疗后嗜中性球的恢復。双磷酸盐虽然对骨骼健康很重要，但与其他药物类型相比，其市占率相对较低。

根据治疗领域，市场分为三类：化疗引起的噁心和呕吐、化疗引起的贫血和嗜中性白血球减少症。化疗引起的噁心和呕吐是主要的治疗领域，主要是因为这些副作用在接受治疗的癌症患者中很常见。其次，化疗引起的贫血位居第二，因为许多患者因治疗而出现红血球数低的情况。中性粒细胞减少症虽然也很重要，但与其他治疗领域相比，其市占率较小。

癌症支持治疗药物市场 - 地理洞察

癌症支持治疗药物市场的地理格局以北美地区的显着增长为特征，特别是在美国，癌症发病率高和先进的医疗基础设施推动了需求。据美国癌症协会称，预计 2024 年美国将新增约 190 万癌症病例，导致支持性护理药物的使用增加。欧洲紧随其后，德国和法国等国家投资于旨在改善癌症护理的创新治疗方案和研究计划。此外，在中国和印度等国家医疗保健支出不断增加以及人们对癌症治疗选择的认识不断提高的推动下，亚太地区正在成为市场扩张的一个值得注意的地区。世界卫生组织强调需要加强发展中地区的癌症护理，进一步推动支持性护理解决方案的成长。因此，公司正在专注于区域合作伙伴关係和量身定制的行销策略，以满足这些不同市场的特定需求。

癌症支持治疗药物市场-竞争格局：

癌症支持治疗药物市场的竞争格局以几个关键参与者的存在为标誌，这些参与者积极致力于开发创新疗法，以满足日益增长的支持治疗需求。安进 (Amgen)、罗氏 (Roche) 和默克 (Merck) 等领先公司正专注于研究和开发，以增强其产品供应，特别是在止吐和粒细胞集落刺激因子 (G-CSF) 领域。例如，安进的 Neulasta（pegfilgrastim）一直是 G-CSF 领域的领导者，有助于降低化疗患者的感染风险。合作和伙伴关係也很常见，例如百时美施贵宝与各种医疗机构结盟以推进支持性护理的研究。此外，最近的收购，例如辉瑞收购 Array BioPharma，增强了公司在癌症治疗领域的投资组合，包括支持性护理药物。随着公司不断创新并扩大业务范围，该市场的竞争仍然激烈，推动了癌症治疗领域的进步，改善了患者的治疗效果。

最新进展：

2023 年 1 月，Helsinn Healthcare SA 和 Immedica Pharma AB 签署了一项独家长期协议，在欧洲主要市场商业化两种癌症支持护理产品 Akynzeo 和 Aloxi，旨在预防化疗引起的噁心和呕吐。

2024 年 8 月，FDA 批准了新一代酪胺酸激酶抑制剂 Augtyro (repotrectinib)，用于治疗 NTRK 阳性局部晚期或转移性实体瘤患者，增强了癌症支持治疗和标靶治疗的选择。

目录

第一章：癌症支持治疗药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类型分類的癌症支持治疗药物市场片段
    • 按治疗领域分類的癌症支持治疗药物市场片段
    • 癌症支持治疗药物市场片段（按分布）
    • 最终用户的癌症支持治疗药物市场片段
    • 按国家/地区分類的癌症支持治疗药物市场片段
    • 按地区分類的癌症支持治疗药物市场片段
  • 竞争洞察

第 3 章：癌症支持治疗药物主要市场趋势

  • 癌症支持治疗药物市场驱动因素
    • 市场驱动因素的影响分析
  • 癌症支持治疗药物市场限制
    • 市场限制影响分析
  • 癌症支持治疗药物市场机会
  • 癌症支持治疗药物市场未来趋势

第 4 章：癌症支持治疗药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：癌症支持治疗药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：癌症支持治疗药物市场格局

  • 2023 年癌症支持治疗药物市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：癌症支持治疗药物市场 - 按药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 红血球生成刺激剂
    • 粒细胞集落刺激因子 (G-CSF)
    • 止吐药
    • 双磷酸盐

第 8 章：癌症支持治疗药物市场 - 按治疗领域

  • 概述
    • 按治疗领域分類的细分市场占有率分析
    • 化疗引起的噁心和呕吐
    • 化疗引起的贫血
    • 嗜中性白血球减少症

第 9 章：癌症支持治疗药物市场 - 按分布

  • 概述
    • 按分布分類的细分市场占有率分析
    • 医院药房
    • 零售药局
    • 网路药局

第 10 章：癌症支持治疗药物市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 儿科患者
    • 成人患者
    • 老年患者

第 11 章：癌症支持治疗药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美癌症支持治疗药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类型）
    • 北美市场规模与预测（按治疗领域）
    • 北美市场规模和预测（按分布）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲癌症支持治疗药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类型）
    • 欧洲市场规模与预测（按治疗领域）
    • 欧洲市场规模和预测（按分布）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区癌症支持治疗药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类型）
    • 按治疗领域分類的亚太市场规模和预测
    • 亚太地区市场规模与预测（按分布）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲癌症支持治疗药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类型）
    • 拉丁美洲市场规模与预测（按治疗领域）
    • 拉丁美洲市场规模与预测（按分布）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲癌症支持治疗药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类型）
    • 中东和非洲市场规模及预测（按治疗领域）
    • 中东和非洲市场规模及预测（按分布）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - 癌症支持治疗药物产业

  • 竞争仪表板
  • 公司简介
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Roche Holding AG
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4105

REPORT HIGHLIGHT

Cancer Supportive Care Drugs Market size was valued at USD 21,410.32 Million in 2023, expanding at a CAGR of 2.31% from 2024 to 2032.

The Cancer Supportive Care Drugs market encompasses medications designed to alleviate the side effects of cancer treatments, enhance patients' quality of life, and support overall health during therapy. Increasing cancer incidence and the rise in treatment options are fueling the demand for supportive care drugs, with the American Cancer Society reporting that approximately 1.9 million new cancer cases are expected in the U.S. in 2024. Moreover, the growing awareness of the importance of palliative care is encouraging healthcare providers to focus on managing treatment-related adverse effects such as nausea, pain, and fatigue. However, challenges such as high costs associated with novel drugs and reimbursement issues can restrain market growth. On the other hand, opportunities lie in the development of personalized supportive care therapies and expanding markets in developing regions, where rising healthcare expenditure and access to innovative treatments are increasing. Additionally, collaborations between pharmaceutical companies and healthcare institutions to enhance drug efficacy and patient outcomes represent a promising avenue for market expansion.

Cancer Supportive Care Drugs Market- Market Dynamics

Rising Cancer Incidence Accelerates Growth in the Cancer Supportive Care Drugs Market

The rising incidence of cancer is significantly driving growth in the Cancer Supportive Care Drugs market, as more patients seek therapies to manage treatment-related side effects. According to the World Health Organization (WHO), cancer is currently the second leading cause of death globally, with nearly 10 million fatalities in 2020. This alarming trend has prompted an increased focus on supportive care options to enhance the quality of life for patients undergoing chemotherapy, radiation, and other treatments. For instance, the American Society of Clinical Oncology (ASCO) emphasizes the importance of managing symptoms such as nausea, pain, and fatigue, which are prevalent among cancer patients. Additionally, organizations like the National Cancer Institute are advocating for research into novel supportive care drugs, further amplifying the demand for effective treatments. As healthcare providers expand their focus on comprehensive cancer care, the market for supportive therapies is expected to flourish, reflecting a critical need to improve patient outcomes in this challenging health landscape.

Cancer Supportive Care Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 2.31% over the forecast period (2024-2032)

Based on Drug Type segmentation, Anti-emetics was predicted to show maximum market share in the year 2023

Based on Therapeutic Area segmentation, Chemotherapy-Induced Nausea, and Vomiting was the leading type in 2023

Based on distribution segmentation, Hospital Pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cancer Supportive Care Drugs Market- Segmentation Analysis:

The Global Cancer Supportive Care Drugs Market is segmented on the basis of Drug Type, Therapeutic Area, Distribution, End-User, and Region.

The market is divided into four categories based on Drug Type: Erythropoiesis-Stimulating Agents, Granulocyte Colony-Stimulating Factors (G-CSFs), Anti-emetics, and Bisphosphonates. Anti-emetics are predicted to show maximum market share due to their essential role in managing chemotherapy-induced nausea and vomiting. Erythropoiesis-stimulating agents follow closely, as they help combat anemia in cancer patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are also significant, supporting neutrophil recovery after chemotherapy. Bisphosphonates, while important for bone health, hold a relatively lower market share compared to the other drug types.

The market is divided into three categories based on Therapeutic Area: Chemotherapy-Induced Nausea and Vomiting, Chemotherapy-Induced Anemia, and Neutropenia. Chemotherapy-induced nausea and Vomiting is the leading therapeutic area, primarily due to the high prevalence of these side effects among cancer patients undergoing treatment. Following this, Chemotherapy-Induced Anemia ranks second, as many patients experience low red blood cell counts due to their therapies. Neutropenia, while also critical, holds a smaller share of the market compared to the other therapeutic areas.

Cancer Supportive Care Drugs Market- Geographical Insights

The geographical landscape of the Cancer Supportive Care Drugs market is characterized by significant growth in North America, particularly in the United States, where a high incidence of cancer and advanced healthcare infrastructure drive demand. According to the American Cancer Society, about 1.9 million new cancer cases were expected in the U.S. in 2024, leading to increased utilization of supportive care drugs. Europe follows closely, with countries like Germany and France investing in innovative treatment options and research initiatives aimed at improving cancer care. Additionally, Asia-Pacific is emerging as a notable region for market expansion, driven by rising healthcare expenditures and increasing awareness of cancer treatment options in countries like China and India. The World Health Organization has emphasized the need for enhanced cancer care in developing regions, further propelling growth in supportive care solutions. As a result, companies are focusing on regional partnerships and tailored marketing strategies to meet the specific needs of these diverse markets.

Cancer Supportive Care Drugs Market- Competitive Landscape:

The competitive landscape of the Cancer Supportive Care Drugs market is marked by the presence of several key players that are actively engaged in developing innovative therapies to meet the growing demand for supportive care. Leading companies such as Amgen, Roche, and Merck are focusing on research and development to enhance their product offerings, particularly in the areas of anti-emetics and granulocyte colony-stimulating factors (G-CSFs). For instance, Amgen's Neulasta (pegfilgrastim) has been a frontrunner in the G-CSF segment, helping to reduce the risk of infection in chemotherapy patients. Collaborations and partnerships are also common, as seen with Bristol-Myers Squibb's alliance with various healthcare institutions to advance research in supportive care. Furthermore, recent acquisitions, such as Pfizer's purchase of Array BioPharma, have strengthened companies' portfolios in cancer therapies, including supportive care drugs. As companies continue to innovate and expand their reach, the competition in this market remains robust, driving advancements that improve patient outcomes in cancer care.

Recent Developments:

In January 2023, Helsinn Healthcare SA and Immedica Pharma AB signed an exclusive long-term agreement to commercialize two cancer-supportive care products, Akynzeo and Aloxi, in key European markets, targeting the prevention of chemotherapy-induced nausea and vomiting.

In August 2024, the FDA approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor, for treating patients with NTRK-positive locally advanced or metastatic solid tumors, enhancing options in cancer supportive care and targeted therapies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Erythropoiesis-Stimulating Agents
  • Granulocyte Colony-Stimulating Factors (G-CSFs)
  • Anti-emetics
  • Bisphosphonates

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy-Induced Nausea and Vomiting
  • Chemotherapy-Induced Anemia
  • Neutropenia

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cancer Supportive Care Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cancer Supportive Care Drugs Market Snippet by Drug Type
    • 2.1.2. Cancer Supportive Care Drugs Market Snippet by Therapeutic Area
    • 2.1.3. Cancer Supportive Care Drugs Market Snippet by Distribution
    • 2.1.4. Cancer Supportive Care Drugs Market Snippet by End-User
    • 2.1.5. Cancer Supportive Care Drugs Market Snippet by Country
    • 2.1.6. Cancer Supportive Care Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Cancer Supportive Care Drugs Key Market Trends

  • 3.1. Cancer Supportive Care Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cancer Supportive Care Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cancer Supportive Care Drugs Market Opportunities
  • 3.4. Cancer Supportive Care Drugs Market Future Trends

4. Cancer Supportive Care Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cancer Supportive Care Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cancer Supportive Care Drugs Market Landscape

  • 6.1. Cancer Supportive Care Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cancer Supportive Care Drugs Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Erythropoiesis-Stimulating Agents
    • 7.1.3. Granulocyte Colony-Stimulating Factors (G-CSFs)
    • 7.1.4. Anti-emetics
    • 7.1.5. Bisphosphonates

8. Cancer Supportive Care Drugs Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy-Induced Nausea and Vomiting
    • 8.1.3. Chemotherapy-Induced Anemia
    • 8.1.4. Neutropenia

9. Cancer Supportive Care Drugs Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Cancer Supportive Care Drugs Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Pediatric Patients
    • 10.1.3. Adult Patients
    • 10.1.4. Geriatric Patients

11. Cancer Supportive Care Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Cancer Supportive Care Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Cancer Supportive Care Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Cancer Supportive Care Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Cancer Supportive Care Drugs Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Cancer Supportive Care Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Cancer Supportive Care Drugs Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Amgen Inc.
    • 12.2.2. AstraZeneca PLC
    • 12.2.3. Bayer AG
    • 12.2.4. Bristol-Myers Squibb Company
    • 12.2.5. Eisai Co., Ltd.
    • 12.2.6. Eli Lilly and Company
    • 12.2.7. F. Hoffmann-La Roche AG
    • 12.2.8. GlaxoSmithKline plc
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Merck & Co., Inc.
    • 12.2.11. Novartis AG
    • 12.2.12. Pfizer Inc.
    • 12.2.13. Roche Holding AG
    • 12.2.14. Sanofi S.A.
    • 12.2.15. Takeda Pharmaceutical Company Limited
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us